Date: 2014-07-08
Type of information: Series B financing round
Company: Sophia Genetics (Switzerland)
Investors: Invoke Capital (UK - USA), Endeavour Vision (Switzerland), Swisscom (Switzerland)
Amount: $13.75 million (€ 10.1 million)
Funding type: series B financing round
Planned used: The company is a pioneer in Data-Driven Medicine, a crossover field that requires deep expertise in Next Generation Sequencing (NGS), combined with highly accurate and scalable predictive algorithms to diagnose genetic diseases. With this investment, Sophia Genetics gains access to Invoke’s portfolio company Genalys, whose Cambridge-based mathematicians apply big data approaches to genomic information. The combination means that clinicians and hospitals across Europe gain access to very accurate clinical analytics service for early diagnosis and optimized treatment of cancer and genetic diseases. Until recently, only researchers had access to the kind of information that Sophia Genetics now puts in the hands of clinicians by providing them with European-certified quality assurance in accuracy, reliability, reproducibility and privacy. Sophia Genetics patent pending genomic privacy approach combined with Invoke’s own expertise in securing patient data means that Sophia Genetics has been founded in March 2011 and has developed bioinformatics pipelines and visualization tools for more than 70 commercial panels, proprietary custom panels and is extending that capability to whole exomes and genomes. The company obtains CE-IVD marking for each supported pipeline and has received ISO 13485 certification.
Others: * On July 8, 2014, Sophia Genetics, an European leader in data-driven medicine, has raised $13.75 million in Series B financing in a round led by Dr Mike Lynch’s Invoke Capital, Endeavour Vision and Swisscom.
Therapeutic area: Genetic diseases
